Abstract LB-105: Plasma exposure-target engagement biomarker analysis for danvatirsen after multiple dosing schedules and route of administrations in patients with advanced solid tumors
Authors: Miah Kowser , McCoon Patricia , Russell Deanna , Mitchell Patrick , Scott Martin , Rosenfeld Amy , Zhang Li , Rodriguez Pablo Martinez , Savage Alicia , Mugundu Ganesh 
Published: September 2020

Background: Danvatirsen (Da) is a generation 2.5 antisense oligonucleotide targeting STAT3 mRNA under clinical development in combination with Durvalumab (NCT03421353). The recommended Phase II dose is intravenous (IV) 200 mg weekly (QW, A). However, alternative 400 mg IV every two weeks (Q2W, B) and subcutaneous 200 mg QW (C) are also under investigation. The JAK-STAT signaling pathway is involved in immunity, cell division, cell death, and tumor formation. Additionally, activation of hepatic STAT3 results in increased secretion of C-reactive protein (CRP) and fibrinogen into blood. Therefore, target engagement in patients may be better understood by analyzing Da exposure and related biomarkers in the blood/plasma. We investigated Da exposure and subsequent impact on target engagement biomarkers such as CRP, platelets, fibrinogen, neutrophils and STAT3 mRNA levels. Methods: Extensive pharmacokinetics (PK) samples were collected at lead-in monotherapy and at steady state (SS) in combination. Plasma biomarker samples were collected at baseline and every two weeks thereafter. Whole blood samples for the analysis of STAT3 mRNA were collected at baseline, after lead-in monotherapy, and every four weeks thereafter. The PK parameters were estimated by non-compartmental analysis by WinNonlin. The biomarkers were analyzed by standard clinical methods and STAT3 mRNA level was measured by NanoString technology. Results: The area under plasma concentration-time curve of Da at SS within dosing interval (AUC0-τ, ng.h/ml) for A, B, and C were 69110 (24.64%), 101600 (22.11%), and 44600 (30.25%), respectively. Additionally, SS Ctrough (ng/ml) levels for A, B, and C were 28.53 (48.86%), 14.56 (36.14%), and 27.66 (49.22%), respectively. Maximum median % decrease from baseline in CRP levels was observed at week 4; A (-91%), B (-94%), C (-82%). Additionally, maximum median % changes from baseline for fibrinogen were -60%, -40%, -53%, in A, B, and C at week 4, respectively. Maximum % decrease from baseline in platelets was observed at week 8 in A (-42%), B (-41%), and C (-69%). In contrast, maximum % change from baseline in neutrophil count was observed at week 6; -37%, -31%, and -32% in A, B, and C, respectively. Additionally, the median maximum change from baseline for STAT3 mRNA was -42.4% and -33.6% for A and C, respectively. Conclusion: Cumulative AUC in A was very similar to B, whereas, AUC in C was 30% lower as compared to A or B. The SS Ctrough values in A and C were similar, although Ctrough value in B was 50% lower. Maximum % decreases in CRP levels were similar across all the doses. Moreover, route of administration did not appear to impact level of STAT3 knockdown. In summary, a similar degree of changes in pharmacodynamic biomarkers were achieved at all three dose levels regardless of route of administration, despite differences in plasma exposure.

Citation Format: Kowser Miah, Patricia McCoon, Deanna Russell, Patrick Mitchell, Martin Scott, Amy Rosenfeld, Li Zhang, Pablo Martinez Rodriguez, Alicia Savage, Ganesh Mugundu. Plasma exposure-target engagement biomarker analysis for danvatirsen after multiple dosing schedules and route of administrations in patients with advanced solid tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-105.